Autolus Therapeutics plc key statistics and ratios

In fiscal 2025, Autolus Therapeutics plc had return on equity of -95.0%, an operating margin of -358.9%, debt equal to 0.0% of equity and a current ratio of 5.94. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Autolus Therapeutics plc: financial ratios, annual
Fiscal year	2016Sept 2016	2017Sept 2017	2018Sept 2018	2019Dec 2019	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Gross margin	—	—	—	—	100.0%	−12.5%	−27.8%	15.7%
Operating margin	—	<−999%	<−999%	<−999%	<−999%	<−999%	−358.9%	−210.8%
Net margin	<−999%	<−999%	<−999%	<−999%	<−999%	<−999%	−381.4%	−238.7%
Free-cash-flow margin	−965.7%	<−999%	<−999%	<−999%	<−999%	<−999%	−401.4%	−198.3%
Return on equity	−40.9%	−22.8%	−22.5%	−48.5%	−113.8%	−81.9%	−95.0%	—
Return on assets	—	−13.3%	−21.2%	−42.9%	−61.4%	−38.1%	−41.9%	−51.8%
Asset turnover	—	0.01	0.01	0.01	0.01	0.02	0.11	0.22
Current ratio	—	28.31	15.13	9.98	6.15	10.88	5.94	4.89
Debt to equity	0.0%	0.5%	0.1%	0.0%	0.0%	0.0%	0.0%	0.0%
Interest cover (operating income ÷ interest)	—	—	—	—	n/m	n/m	n/m	n/m
R&D as % of revenue	861.1%	945.8%	>999%	>999%	>999%	>999%	156.1%	95.9%
SG&A as % of revenue	—	—	—	—	>999%	>999%	174.9%	130.5%
Capital spending as % of revenue	153.1%	169.9%	648.1%	630.7%	647.0%	218.1%	25.3%	6.1%

US$ thousands unless shown otherwise. Fiscal quarters.

Autolus Therapeutics plc: financial ratios, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Gross margin	—	—	−99.9%	−16.8%	−35.1%	−4.3%	6.3%	55.2%
Operating margin	—	<−999%	−726.3%	−292.6%	−337.9%	−298.3%	−227.0%	−95.9%
Net margin	—	<−999%	−781.1%	−229.0%	−373.3%	−371.9%	−273.1%	−85.6%
Free-cash-flow margin	—	<−999%	−933.1%	−382.6%	−341.2%	−273.5%	−259.4%	−56.9%
Current ratio	13.69	10.88	9.24	8.43	6.19	5.94	5.80	4.89
R&D as % of revenue	—	>999%	297.6%	131.1%	131.6%	146.7%	80.9%	61.1%
SG&A as % of revenue	—	>999%	328.8%	144.6%	171.2%	147.4%	152.4%	90.1%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

1 of 3 checks passed · June 30, 2026

What it owns · $493m

Short-term assets $336mLonger-term assets $157m

What it owes, and who funded it · $493m

Short-term liabilities $69mLonger-term liabilities $350mShareholders' equity $75m

Short-term assets cover short-term liabilities $336m of assets due within a year against $69m of liabilities due within a year.
Short-term assets cover long-term liabilities $336m short-term assets against $350m of longer-dated liabilities.
More cash than debt Cash or debt not separately reported. Not assessable.
Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
Operating profit covers interest at least five times over Operating income of −$247m against $42m of interest.

From Autolus Therapeutics plc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: AUTL vs RCUS AUTL vs SPRY AUTL vs MESO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Autolus Therapeutics plc's SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Autolus Therapeutics plc.